Skip to main content

Transplantation Infection

4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
1
2
EverolimusPhase 41 trial
EverolimusPhase 41 trial
Everolimus 0.25 and 0.75 mg tabletsPhase 31 trial
Active Trials
NCT01276457Completed223Est. Feb 2009
NCT02328963Completed186Est. Oct 2018
NCT02084446Completed120Est. Jul 2017
ADMA Biologics
ADMA BiologicsNJ - Ramsey
1 program
1
Hepatitis C Immune Globulin Intravenous (Human)Phase 2
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
immunization appN/A1 trial
Active Trials
NCT04336735Unknown45Est. Aug 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozEverolimus
SandozEverolimus
SandozEverolimus 0.25 and 0.75 mg tablets
Colorado Therapeuticsimmunization app

Clinical Trials (4)

Total enrollment: 574 patients across 4 trials

NCT02328963SandozEverolimus

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A

Start: May 2014Est. completion: Oct 2018186 patients
Phase 4Completed
NCT02084446SandozEverolimus

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Start: Dec 2012Est. completion: Jul 2017120 patients
Phase 4Completed
NCT01276457SandozEverolimus 0.25 and 0.75 mg tablets

Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients

Start: May 2006Est. completion: Feb 2009223 patients
Phase 3Completed
NCT04336735Colorado Therapeuticsimmunization app

Improving Immunization Rates in Transplant Candidates Through the Use of a Health Information Technology Tool

Start: Jan 2022Est. completion: Aug 202445 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.